citalopram has been researched along with Autism Spectrum Disorder in 7 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability." | 7.81 | Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. ( Bishop, JR; Cook, EH; Guter, SJ; Jacob, S; Mosconi, MW; Najjar, F; Owley, T; Rubin, LH, 2015) |
| "The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD)." | 5.20 | Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism. ( Bishop, JR; Cook, EH; Gibbons, RD; Guter, SJ; Hur, K; Jacob, S; Mosconi, MW; Najjar, F; Owley, T; Sweeney, JA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, NM | 1 |
| Dipasquale, O | 1 |
| Turkheimer, F | 1 |
| Findon, JL | 2 |
| Wichers, RH | 2 |
| Dimitrov, M | 1 |
| Murphy, CM | 2 |
| Stoencheva, V | 2 |
| Robertson, DM | 2 |
| Murphy, DG | 1 |
| Daly, E | 1 |
| McAlonan, GM | 1 |
| Simonoff, E | 1 |
| Mowlem, F | 1 |
| Pearson, O | 1 |
| Anagnostou, E | 1 |
| Donnelly, C | 1 |
| Hollander, E | 1 |
| King, BH | 1 |
| McCracken, JT | 1 |
| Scahill, L | 1 |
| Sikich, L | 1 |
| Pickles, A | 1 |
| Jelsma, A | 1 |
| Giampietro, V | 1 |
| McAlonan, G | 1 |
| Ecker, C | 1 |
| Rubia, K | 1 |
| Murphy, DGM | 1 |
| Daly, EM | 1 |
| Cai, Y | 1 |
| Wang, L | 1 |
| Nalvarte, I | 1 |
| Xiao, R | 1 |
| Li, X | 1 |
| Fan, X | 1 |
| Thorkelson, G | 1 |
| Laughlin, SF | 1 |
| Turner, KS | 1 |
| Ober, N | 1 |
| Handen, BL | 1 |
| Najjar, F | 2 |
| Owley, T | 2 |
| Mosconi, MW | 2 |
| Jacob, S | 2 |
| Hur, K | 1 |
| Guter, SJ | 2 |
| Sweeney, JA | 1 |
| Gibbons, RD | 1 |
| Cook, EH | 2 |
| Bishop, JR | 2 |
| Rubin, LH | 1 |
1 review available for citalopram and Autism Spectrum Disorder
| Article | Year |
|---|---|
Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review.
Topics: Adolescent; Anxiety Disorders; Autism Spectrum Disorder; Citalopram; Comorbidity; Female; Fluoxetine | 2019 |
4 trials available for citalopram and Autism Spectrum Disorder
| Article | Year |
|---|---|
Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial.
Topics: Adult; Autism Spectrum Disorder; Brain; Citalopram; Cross-Over Studies; Humans; Magnetic Resonance I | 2022 |
Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors.
Topics: Adolescent; Anxiety; Anxiety Disorders; Autism Spectrum Disorder; Child; Citalopram; Humans; Selecti | 2022 |
Modulation of brain activation during executive functioning in autism with citalopram.
Topics: Adult; Attention; Autism Spectrum Disorder; Brain; Brain Mapping; Citalopram; Cross-Over Studies; Do | 2019 |
Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Child, Preschool; Citalopram; Dose-Response Rela | 2015 |
2 other studies available for citalopram and Autism Spectrum Disorder
| Article | Year |
|---|---|
Citalopram attenuates social behavior deficits in the BTBR T
Topics: Animals; Autism Spectrum Disorder; Behavior, Animal; Citalopram; Disease Models, Animal; Grooming; M | 2019 |
Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Child, Preschool; Citalopram; Cytochrome P-450 C | 2015 |